FDA will hold a public meeting on June 10 to explore setting up a user fee program to help fund reviews of over-the-counter (OTC) drug monographs, saying the agency's OTC program is severely under resourced and reviews could stall. The Consumer Health Products Association (CHPA), the OTC drug lobby, told Inside Health Policy it agrees the agency needs additional resources in this area and welcomes the chance to discuss the pros and cons of a targeted user fee program...